The fate of the ovaries after radical hysterectomy and ovarian transposition.
To assess the effectiveness of lateral ovarian transposition in preserving normal ovarian function, the medical records of 200 consecutive women with stage I-IIA cervical cancer treated primarily with radical hysterectomy and pelvic lymphadenectomy were reviewed. Lateral ovarian transposition was performed at the time of radical hysterectomy in 132 (66%) patients and 28 (21%) received postoperative pelvic radiation therapy. Menopausal symptoms (vaginal dryness, hot flushes) and follicle-stimulating hormone (FSH) levels were used to define ovarian function. Only 3/104 (2.9%) patients who underwent lateral ovarian transposition without postoperative pelvic radiotherapy experienced menopausal symptoms; however, FSH levels in all three cases suggested continued ovarian function. In 14/28 (50%) patients who received postoperative pelvic radiation therapy ovarian failure occurred. The risk of ovarian failure with pelvic radiation therapy after lateral ovarian transposition was significant (RR = 17.3; 95% CI = 5.35-56.13). The incidence of adnexal disease in transposed ovaries requiring analgesics or further surgery was 3%. These data suggest minimal risk to the patient when the ovaries are conserved. Unfortunately, lateral ovarian transposition preserves ovarian function in only 50% of patients undergoing pelvic radiotherapy following radical hysterectomy.
Feeney
D D
DD
Department of Obstetrics and Gynecology, Indiana University Medical Center, Indianapolis 46202-5274.
Moore
D H
DH
Look
K Y
KY
Stehman
F B
FB
Sutton
G P
GP
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D008197:Lymph Node Excision; D008593:Menopause / Q000502:physiology; D008875:Middle Aged; D010048:Ovarian Cysts / Q000209:etiology; D010049:Ovarian Diseases / Q000209:etiology; D010053:Ovary / Q000502:physiology*; D014102:Torsion Abnormality; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy / Q000601:surgery*
D005640:Follicle Stimulating Hormone